November, 2012

Results of Annual General Meeting

Change of Director’s Interest Notice: Washer

Change of Director’s Interest Notice: Dantzker

Change of Director’s Interest Notice: Korten

Change of Director’s Interest Notice: Haghighat

Change of Director’s Interest Notice: MacDonald

October, 2012

iSonea Q1 Report 2013

ISN ASX Confirm Rights Issue Shortfall

Notice of Annual General Meeting and Explanatory Memorandum

Dispatch of Renounceable Pro-Rate Rights Issue Prospectus

iSonea Files FDA Submission for Over-the-Counter SonoSentry™

September, 2012

2012 Annual Report

Letter to Eligible Shareholders on Rights Issue

Letter to Ineligible Shareholders on Rights Issue

iSonea Announces Fully Underwritten Renounceable Rights Issue to Raise $4M

Appendix 3B: application for quotation of additional securities and agreement

Prospectus: Offer to Eligible Shareholders

Letter to Option Holders

iSonea App Now Free




Pulmotrack® - Respiratory Acoustic Monitor

Innovative New Tool for Wheeze Identification,
Characterization and Quantification


PulmoTrack® enables the continuous monitoring of wheezes, even in cases without patient cooperation. In addition to quantifying and recording each wheeze, PulmoTrack® provides:

  • Wheeze by wheeze identification
  • Accurate measurement of Wheeze Rate (the proportion of wheezing in the respiratory cycle)
  • Respiratory rate & I\E ratio
  • Classification of wheezes as inspiratory or expiratory
  • Cough Counting (FDA Pending)

PulmoTrack®, the first solution of its kind for continuous and nocturnal monitoring, is recommended for use to diagnose and manage a variety of respiratory illnesses, particularly where wheezes or coughs serve as clinical parameters.

The PulmoTrack® Respiratory Acoustic Monitor can be used for:

  • Bronchodilation Test: Measurement of response to treatment
  • Bronchoprovocation Test: Particularly for infants or other non-cooperative patient
  • Performance of physical examination: In a pulmonary function testing environment to identify and quantify the presence of wheezing

PulmoTrack® Facilitates Better Patient Management

  • Minimum patient active effort offers previously unavailable objective pulmonary symptoms documentation in all age group and continuous overnight monitoring.
  • Precise measurement of wheeze rate provides quantitative patient data.
  • Archivable and retrievable reports over a period of time enable the following of symptom trends.
  • Detailed graphic spectral display and acoustic playback features allow the review of specific records for secondary data analysis.


PulmoTrack® Brochure 

User Manual

Sensors Placement Instructions 

CE certificate

FDA Clearance

© 2012 iSonea (formerly Karmelsonix) Ltd| Disclaimer, Terms and Conditions, Copyright and Intellectual Property.

BlackFin Processor
BlackFin® Processor
KarmelSonix ISO Certification
ISO Certification 2003
US Food & Drug Administration

US Food & Drug Administration
Australian Government

Australian Government
Therapeutic Goods Administration

CE Certification

CE Certification